Insider Trading November 20, 2026 02:16 AM

Zomedica Director Powers Adds 175,000 Shares as Stock Slips

The $14,525 purchase raises Johnny D. Powers' direct stake to 4.6 million shares amid a weekly decline in ZOMDF.

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
ZOMDF

Johnny D. Powers, a director at Zomedica Corp. (NASDAQ:ZOMDF), bought 175,000 shares of common stock on November 19, 2026, at $0.083 per share, for a total of $14,525. The transaction lifts his direct holdings to 4,600,000 shares. The purchase occurred as the stock has fallen roughly 16% over the past week and was trading at $0.08. An analysis cited in the report indicates Zomedica appears undervalued at current levels, with a Fair Value estimate pointing to potential upside. The company has a strong balance sheet, holding more cash than debt and a current ratio of 6.09, but remains unprofitable. The article also notes that additional exclusive tips are available for ZOMDF investors through a subscription service.

Zomedica Director Powers Adds 175,000 Shares as Stock Slips
ZOMDF
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director Johnny D. Powers bought 175,000 Zomedica shares at $0.083 each, totaling $14,525, and now directly holds 4.6 million shares.
  • The purchase occurred as ZOMDF has fallen about 16% over the past week and was trading at $0.08.
  • An analysis cited in the report indicates Zomedica appears undervalued, with a Fair Value estimate suggesting potential upside, supported by a strong balance sheet (more cash than debt, current ratio of 6.09) despite ongoing unprofitability.

Zomedica Corp. (NASDAQ:ZOMDF) director Johnny D. Powers acquired 175,000 shares of the company’s common stock on November 19, 2026, according to a recent disclosure. The shares were purchased at $0.083 each, bringing the total value of the transaction to $14,525.

Following the acquisition, Mr. Powers directly holds 4,600,000 shares of Zomedica common stock. The purchase comes as the stock has declined roughly 16% over the past week, with shares trading at $0.08.

An analysis of the company’s valuation suggests that Zomedica appears undervalued at current levels. A Fair Value estimate indicates potential upside for the stock, though the company remains unprofitable. On the balance sheet, Zomedica maintains a strong position with more cash than debt and a current ratio of 6.09.

Investors seeking further insight can access additional exclusive tips for ZOMDF through a subscription service.

The transaction provides a signal of director-level confidence at a time when the share price has been under pressure. However, the article does not speculate on the reasons behind the purchase or the recent price decline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Risks

  • Zomedica remains unprofitable, which could continue to weigh on the stock.
  • The stock has declined roughly 16% over the past week, indicating recent negative price momentum.
  • The Fair Value estimate and undervaluation assessment are based on a third-party analysis and may not prove accurate.

More from Insider Trading

Acrivon CEO Offloads $2,581 in Shares to Cover Tax Bill Nov 20, 2026 PPL Finance Chief Henninger Offloads $87,475 in Stock Under Pre-Set Trading Plan Nov 20, 2026 PayPal Global Markets President Offloads $241K in Shares Under Pre-Arranged Plan Nov 20, 2026 Braze Accounting Chief Offloads $100K in Shares Under Sell-to-Cover Plan Nov 20, 2026 WEX Director Lauren Taylor Wolfe Offloads $2.9 Million in Stock Nov 20, 2026